Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population

Overview

The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.

Study Type

  • Study Type: Expanded Access

Interventions

  • Drug: Plasminogen
    • Human Plasminogen

Participating in This Clinical Trial

Inclusion Criteria

  • Subjects diagnosed with LC associated with Type I plasminogen deficiency, confirmed by laboratory documentation at screening visit, with or without ocular pseudomembranes. The presence of membranes in different areas is not an exclusion criterion. – Subjects and their legally authorized representative, in the case of subjects <18 years of age, should be informed of the nature of the treatment, agree to its provision, sign and date the informed and data handling consent forms approved by the IRB. – Subjects must be available for the duration of the treatment and agree to be compliant with the protocol visit and follow-up schedule. – Subjects agree to keep the treating physician or specialist in charge informed about any occurrence related to the treatment. Exclusion Criteria:

  • Subjects with any condition which, in the opinion of the treating physician or specialist in charge might interfere with the treatment. – Females of childbearing potential who are either pregnant or not using an adequate method of birth control (adequate is defined as hormonal contraceptive or partner vasectomy for at least 3 months, condoms, intrauterine device [IUD], abstinence or other prescribed birth control). Enrolled males must agree to utilize appropriate contraceptive methods to prevent pregnancy in partners. – Females who are breastfeeding.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Investigator Details

  • Lead Sponsor
    • Kedrion S.p.A.
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Anna Lotti Suffredini, 00390583767324, a.lotti@kedrion.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.